Unusual presentation of herpes virus infections in renal transplant recipients exposed to high mycophenolic acid plasma concentrations

Transplant Infectious Disease

Volumn 5, Issue 2, 2003, Pages 79-83

  Smak Gregoor, Peter J H ^a   Van Gelder, T ^a   Van Riemsdijk van Overbeeke, I C ^a   Vossen, A C T M ^a   IJzermans, J N M ^a   Weimar, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cytomegalovirus; Infection; Mycophenolate mofetil; Mycophenolic acid; Therapeutic drug monitoring; Transplantation

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALACICLOVIR; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

ADULT; CYTOMEGALOVIRUS; FEMALE; GRAFT REJECTION; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MONITORING, IMMUNOLOGIC; MYCOPHENOLIC ACID; SIMPLEXVIRUS;

EID: 0141533286     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2003.00012.x     Document Type: Article

References (29)

1. FISHMAN JA, RUBIN RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741-1751.
2. Causes of death. USRDS 1999 Annual Data Report, 1999: 89-100.
3. SARMIENTO JM, DOCKRELL DH, SCHWAB TR, MUNN SR, PAYA CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000: 14: 136-138.
4. CAILHIER JF, BOUCHER A, BELIVEAU C, et al. CMV in kidney transplants in the tacrolimus-mycophenolate era. Transplant Proc 2001: 33: 1196-1197.
5. SMAK GREGOOR PJH, HESSE CJ, VAN GELDER T, et al. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. Transplant Proc 1998: 30: 1192-1193.
6. JACQZ-AIGRAIN E, KHAN SE, BAUDOUIN V, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000: 14: 95-99.
7. SMAK GREGOOR PJH, DE SÉVAUX RG, HENÉ RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999: 68: 1603-1606.
8. SMAK GREGOOR PJH, VAN GELDER T, HESSE CJ, VAN DER MAST BJ, VAN BESOUW NM, WEIMAR W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999: 14: 706-708.
9. VAN GELDER T, HILBRANDS LB, VANRENTERGHEM Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999: 68: 261-266.
10. OELLERICH M, SHIPKOVA M, SCHUTZ E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000:22:20-26.
11. US RENAL TRANSPLANT MYCOPHENOLATE MOFETIL STUDY GROUP. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999: 34: 296-303.
12. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321-1325.
13. THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029-1037.
14. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999: 68: 391-396.
15. TER MEULEN CG, WETZELS JF, HILBRANDS LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000: 15: 711-714.
16. FOLKMANE I, CHAPENKO S, AMERIKA D, BICANS J, MUROVSKA M, ROSENTALS R. Beta-herpesvirus activation after kidney transplantation with mycophenolate mofetil-based maintenance immunosuppression. Transplant Proc 2001: 33: 2384-2385.
17. KAPLAN B, MEIER-KRIESCHE HU, JACOBS MG, et al. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis 1999: 34: 65-68.
18. SMAK GREGOOR PJH, VAN GELDER T, ABRAHAM TA, CHADHA-AJWANI S, KLAASSEN RJ, WEIMAR W. Cytomegalovirus colitis in a CMV-seropositive renal transplant recipient on triple drug therapy (including mycophenolate). Nephrol Dial Transplant 1997: 12: 2766-2767.
19. ISENBERG AL, SHEN GK, SINGH TP, HAHN A, CONTI DJ. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy. Clin Transplant 2000: 14: 193-198.
20. ROTHWELL WS, GLOOR JM, MORGENSTERN BZ, MILLINER DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999: 68: 158-161.
21. FILLER G, ZIMMERING M, MAI I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000: 14: 100-104.
22. SMAK GREGOOR PJH, VAN GELDER T, VAN BESOUW NM, VAN DER MAST BJ, IJZERMANS JN, WEIMAR W. Randomised study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000: 70: 143-148.
23. RUBIN RH, WOLFSON JS, COSIMI AB, TOLKOFF-RUBIN NE. Infection in the renal transplant recipient. Am J Med 1981: 70: 405-411.
24. GALLAGHER H, ANDREWS PA. Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link? Drug Saf 1901: 24: 405-412.
25. VINCENTI F, KIRKMAN R, LIGHT S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998: 338: 161-165.
26. ALLISON AC, EUGUI EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996: 10: 77-84.
27. KIMBALL JA, PESCOVITZ MD, BOOK BK, NORMAN DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995: 60: 1379-1383.
28. FISHMAN JA, DORAN MT, VOLPICELLI SA, COSIMI AB, FLOOD JG, RUBIN RH. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000: 69: 389-394.
29. TURGEON N, FISHMAN JA, DORAN M, et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transpl Infect Dis 2000: 2: 2-10.